Retatrutide vs Tirzepatide: What the Research Shows

Retatrutide and tirzepatide are both once-weekly incretin peptides developed by Eli Lilly, but they differ in one fundamental way: tirzepatide activates two receptors (GIP and GLP-1) while retatrutide activates three (GIP, GLP-1 and glucagon). In published trials, tirzepatide produced up to 20.9% mean weight reduction at 72 weeks (SURMOUNT-1) and retatrutide 24.2% at 48 weeks in phase 2, rising to 28.3% at 80 weeks in the 2026 TRIUMPH-1 phase 3. In the UK, tirzepatide is an MHRA-licensed medicine as Mounjaro, whereas retatrutide is investigational with no licence. This article compares retatrutide vs tirzepatide across mechanism, data, tolerability and legal status.

Retatrutide vs tirzepatide: the mechanism

Both compounds are synthetic peptides built on a modified gut-hormone backbone with a fatty-acid chain that binds albumin and gives a half-life of around five to six days. The difference is in receptor pharmacology.

The addition of glucagon receptor activity is the whole story of retatrutide. Glucagon on its own raises blood glucose, which is why it has historically been avoided in metabolic drug design. Paired with GLP-1 and GIP activity, however, the glucose-raising effect is counterbalanced, leaving the energy-expenditure and liver-fat effects that researchers are most interested in. The phase 2 liver sub-study reported liver-fat reductions of more than 80% in some retatrutide arms, a figure not seen with dual agonists.

The headline trial data side by side

Tirzepatide's pivotal obesity trial was SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 adults with obesity or overweight without diabetes, randomised to 5, 10 or 15 mg weekly or placebo for 72 weeks. Mean weight reduction was 15.0%, 19.5% and 20.9% respectively, against 3.1% on placebo; the efficacy estimand, which assumes participants stayed on treatment, put the top figure at 22.5%.

Retatrutide's phase 2 (Jastreboff et al., NEJM 2023) was smaller: 338 adults over 48 weeks across doses of 1 to 12 mg. The 12 mg group reached 24.2% at 48 weeks and had not plateaued. The phase 3 TRIUMPH-1 trial, reported in May 2026, enrolled 2,339 adults and produced 28.3% at 80 weeks and 30.3% at 104 weeks in the 12 mg extension. TRIUMPH-2 and TRIUMPH-3 (July 2026) reported up to 22.6% in harder-to-treat populations with type 2 diabetes and cardiovascular disease.

Why cross-trial comparisons need care

Putting these numbers in one table is useful, but it is not a head-to-head comparison. No published trial has randomised participants directly between retatrutide and tirzepatide. The trials differ in duration (48 versus 72 versus 80 weeks), baseline weight, escalation schedules, geography and the statistical estimand used to report results. Retatrutide's phase 2 was also a much smaller study, and phase 2 results often shrink slightly in phase 3.

The safest reading of the literature is that retatrutide appears to produce greater weight reduction than tirzepatide over comparable timeframes, that the difference is likely in the region of several percentage points rather than double, and that retatrutide's curves in both phase 2 and TRIUMPH-1 had not flattened when measurement stopped. Lilly is running a direct comparison in the TRIUMPH programme, which will settle the question properly.

Tolerability reported in trials

Both compounds share the gastrointestinal profile typical of the incretin class: nausea, diarrhoea, vomiting and constipation, mostly mild to moderate and clustered around dose escalation. In SURMOUNT-1, treatment discontinuation because of adverse events was 4.3% to 7.1% across tirzepatide arms versus 2.6% for placebo. In retatrutide's phase 2, the equivalent figure ranged from about 6% to 16% depending on dose and escalation schedule, with slower escalation reducing the burden.

Retatrutide has two additional signals reported by investigators that tirzepatide does not share to the same degree: a larger early increase in heart rate, thought to relate to glucagon receptor activity, and dose-dependent skin dysaesthesia (tingling or altered sensation) in a minority of participants. TRIUMPH-1 described gastrointestinal events as generally mild and infrequently leading to discontinuation. Since 2025 the MHRA has also strengthened warnings across all licensed GLP-1 and GLP-1/GIP medicines regarding rare cases of acute pancreatitis, which applies to Mounjaro as a licensed product.

UK legal and regulatory status

This is the sharpest difference between the two. Tirzepatide holds an MHRA marketing authorisation: it was licensed as Mounjaro for type 2 diabetes and then for weight management in November 2023, and NHS England began a phased rollout for eligible patients in June 2025. Retatrutide has no marketing authorisation from the MHRA, the EMA or the FDA and cannot be prescribed.

For research suppliers, the existence of Mounjaro creates an extra obligation with tirzepatide. Research-grade tirzepatide must never be presented as equivalent to or a substitute for the licensed product; it has not been made under a pharmaceutical licence or gone through batch release. Retatrutide carries no such confusion because there is no licensed comparator, but it is equally unlawful to promote it for human use. Both are supplied by Calibre strictly for laboratory research.

What each compound is being investigated for

Tirzepatide has the larger published evidence base. Beyond SURMOUNT and the SURPASS diabetes trials, it has reported outcomes in obstructive sleep apnoea (SURMOUNT-OSA), heart failure with preserved ejection fraction (SUMMIT) and diabetes prevention (SURMOUNT-1 three-year data, NEJM 2024). For a laboratory, that means well-characterised reference points against which a dual agonist can be studied.

Retatrutide's programme is newer but broader in ambition: obesity with and without diabetes, knee osteoarthritis, cardiovascular disease, chronic kidney disease, sleep apnoea and MASLD. Its unique glucagon activity makes it the compound of choice for research into hepatic fat and energy expenditure, and for comparative receptor pharmacology against single and dual agonists.

Research material: strength, purity and cost

Both peptides are supplied as research chemicals in pre-filled pens. Calibre offers retatrutide at 10, 20, 30 and 40 mg and tirzepatide at 50 and 60 mg, each pre-filled and precision made, targeting greater than 99% purity, with every batch tested by Janoshik Analytical and the certificate of analysis published on the COA page. Retatrutide is typically the more expensive per milligram because of demand and synthesis complexity; tirzepatide is more established and more widely available.

Whichever compound a laboratory is working with, the checks are identical: a batch-matched COA, HPLC purity above 99%, a mass spectrometry result consistent with the theoretical mass, and a supplier that makes no claims about human use. For a fuller checklist see our guide to buying research peptides in the UK.